MAMMI-BB PET for Monitoring Response to Neoadjuvant Therapy in Breast Cancer

Study acronym: MAMMI-PREDICT
StatusActive, Not Recruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Fudan University
634 trials monitored
See 8 trials at risk
Breast Cancer
5,455 trials monitored
See 306 trials at risk
This prospective, single-center, open-label, single-arm study will evaluate MAMMI-BB positron emission tomography (PET) for monitoring response to neoadjuvant therapy in patients with breast cancer and baseline axillary lymph node involvement. Serial PET examinations will measure changes in maximum standardized uptake value (SUVmax) in breast lesions and axillary lymph nodes. These changes will be compared with surgical pathology to assess their ability to predict pathologic complete response separately in the breast and axilla and to identify the most informative assessment time point. Associations between PET parameters and long-term outcomes, including progression-free survival and disease-free survival, will also be explored.
Trial Details
NCT Number NCT07875244
Lead Sponsor Fudan University
Conditions
(from sponsor)		 Breast Cancer, Neoadjuvant Therapy, Axilla; Breast
Related terms Breast Neoplasms
Enrollment 1,024 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov